Monday, February 16, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

How Confident Are You in RFK Jr.’s Health Leadership?

Survey: Public Confidence in RFK Jr.’s Leadership in Health Policy

Response scale for all items:
Strongly disagree · Disagree · Neither agree nor disagree · Agree · Strongly agree

RFK Jr.’s prior work as an environmental attorney is relevant and beneficial to health policy leadership roles.
I am confident in RFK Jr.’s overall ability to lead and oversee national health policy institutions.
RFK Jr.’s public criticisms of segments of the pharmaceutical industry align with my understanding of current policy and market challenges.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight reduce my confidence in his health policy judgment.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight do not reduce my confidence in his health policy judgment.
RFK Jr.’s communication style and public persona support effective collaboration with scientific and regulatory stakeholders
RFK Jr.’s communication style and public persona could make it harder to build consensus across health agencies and expert groups.
RFK Jr.’s disclosed history of substance use disorder does not affect my assessment of his present capacity for public leadership.
RFK Jr.’s disclosed history of substance use disorder raises concerns for me about suitability for senior public leadership roles.
RFK Jr.’s policy positions indicate a willingness to challenge existing regulatory and industry frameworks in ways that could improve public health outcomes.
RFK Jr.’s policy positions introduce a level of uncertainty that could increase risk in national health decision-making.
I have sufficient familiarity with RFK Jr.’s public statements and policy positions to make a confident judgment about his leadership suitability.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!